Related Experiment Videos
AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin
E Caumes1, G Guermonprez, C Katlama
1Département de Médecine Tropicale, Maladies Infectieuses, Parasitologie, Mycologie et Santé Publique, Hôpital de la Salpêtrière, Paris, France.
AIDS (London, England)
|December 1, 1992
Summary
Bleomycin effectively treats AIDS-associated mucocutaneous Kaposi
Area of Science:
- Oncology
- Infectious Diseases
- Dermatology
Background:
- AIDS-associated mucocutaneous Kaposi's sarcoma is a significant clinical challenge.
- Previous research suggested bleomycin's potential efficacy.
Purpose of the Study:
- To assess the effectiveness and tolerability of bleomycin for AIDS-associated mucocutaneous Kaposi's sarcoma.
Main Methods:
- Prospective, open-label, non-comparative study.
- Seventy patients received intramuscular bleomycin (5 mg/day for 3 consecutive days every 2 weeks).
Main Results:
- Overall response rate was 74% (2 complete, 50 partial responses).
- Median time to response was 4 weeks; median time to relapse was 10 weeks.
- Cutaneous adverse reactions were the dose-limiting toxicity.
Conclusions:
- Bleomycin demonstrates activity against AIDS-associated mucocutaneous Kaposi's sarcoma.
- Relapse is common after therapy cessation.